Pensionfund Sabic Purchases New Shares in Colgate-Palmolive Company $CL

Pensionfund Sabic bought a new position in shares of Colgate-Palmolive Company (NYSE:CL) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 16,900 shares of the company’s stock, valued at approximately $1,335,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vermillion & White Wealth Management Group LLC boosted its holdings in Colgate-Palmolive by 86.1% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 335 shares of the company’s stock worth $30,000 after purchasing an additional 155 shares during the period. Copia Wealth Management bought a new position in Colgate-Palmolive in the 3rd quarter worth about $29,000. Cloud Capital Management LLC acquired a new stake in Colgate-Palmolive in the 3rd quarter valued at approximately $30,000. Global Wealth Strategies & Associates increased its holdings in shares of Colgate-Palmolive by 300.0% during the fourth quarter. Global Wealth Strategies & Associates now owns 400 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the period. Finally, Grove Bank & Trust increased its stake in Colgate-Palmolive by 182.6% during the 4th quarter. Grove Bank & Trust now owns 407 shares of the company’s stock valued at $32,000 after buying an additional 263 shares during the period. Institutional investors own 80.41% of the company’s stock.

Insider Activity at Colgate-Palmolive

In other news, COO Panagiotis Tsourapas sold 35,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $94.61, for a total transaction of $3,311,350.00. Following the transaction, the chief operating officer directly owned 10,415 shares in the company, valued at $985,363.15. The trade was a 77.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sally Massey sold 15,851 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $95.03, for a total value of $1,506,320.53. Following the sale, the insider owned 13,751 shares of the company’s stock, valued at approximately $1,306,757.53. This represents a 53.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 184,683 shares of company stock worth $17,486,693 in the last 90 days. 0.41% of the stock is owned by corporate insiders.

Colgate-Palmolive Stock Down 0.8%

NYSE:CL opened at $84.46 on Wednesday. The business’s fifty day moving average price is $91.10 and its 200 day moving average price is $83.36. The firm has a market capitalization of $68.08 billion, a price-to-earnings ratio of 32.24, a PEG ratio of 3.81 and a beta of 0.28. The company has a current ratio of 0.83, a quick ratio of 0.54 and a debt-to-equity ratio of 18.82. Colgate-Palmolive Company has a 1-year low of $74.54 and a 1-year high of $99.33.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.04. The firm had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.13 billion. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $0.91 EPS. On average, sell-side analysts forecast that Colgate-Palmolive Company will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 2.5%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 79.39%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CL shares. Deutsche Bank Aktiengesellschaft increased their price target on Colgate-Palmolive from $83.00 to $90.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. Argus reaffirmed a “hold” rating on shares of Colgate-Palmolive in a research note on Thursday, December 11th. Royal Bank Of Canada upgraded shares of Colgate-Palmolive from a “sector perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research report on Tuesday, December 9th. Evercore upped their price target on shares of Colgate-Palmolive from $94.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, February 2nd. Finally, TD Cowen restated a “buy” rating on shares of Colgate-Palmolive in a research report on Monday, February 2nd. Eleven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.75.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.